v3.19.1

Condensed Consolidated Statements Of Operations - USD ($)	3 Months Ended
	Feb. 28, 2019	Feb. 28, 2018
Income Statement [Abstract]
Revenue	$ 0	$ 0
Cost of Revenue	0	0
Gross Profit	0	0
Operating expenses
Consulting fees	55,690	115,343
Consulting fee - related party	89,137	320,192
Depreciation	2,723	2,730
General and administrative	38,666	36,263
General and administrative - related party	16,397	60,515
Rent	28,050	13,185
Total operating expenses	230,663	548,228
Loss before other income (expense)	(230,663)	(548,228)
Other income (expense)
Change in fair value of derivative liabilities	(353,949)	(111,519)
Interest expense	(27,007)	(18,238)
Gain (loss) on settlement of debt	16,833	94,743
Unrealized loss on marketable securities	(4,600)	0
Total other income (expense)	(368,723)	(35,014)
Net loss	(599,386)	(583,242)
Less: loss attributed to non-controlling interest	22,214	0
Net loss to Gala Pharmaceuticals Inc.	$ (577,172)	$ (583,242)
Net loss per share, basic and diluted	$ (0.01)	$ (0.01)
Weighted average common shares outstanding, basic and diluted	94,133,908	40,202,240

The aggregate cost of goods produced and sold and services rendered during the reporting period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Gala Pharmaceutical Inc. 10-Q